Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells
Open Access
- 28 March 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 24 (5) , 851-859
Abstract
As it has been demonstrated that the heat shock protein 90 (HSP90) is required for the assembly and activation of telomerase in human cells, we investigated the effect exerted by the ansamycin antibiotics geldanamycin (GA) and 17-allylamino,17-demethoxygeldanamycin (17-AAG), two well-known inhibitors of the HSP90 chaperone function, on telomerase activity in JR8 human melanoma cells. Using an antibody to HSP90, we precipitated the telomerase activity associated with the molecular chaperone. The results of TRAP (telomeric repeat amplification protocol) experiments carried out on HSP90 immunoprecipitates showed that exposure to 100 ng/ml GA and 17-AAG induced a significant ( P < 0.01) inhibition of telomerase activity, which was observed at earlier time points than drug-induced inhibition of cell proliferation. Superimposable results were obtained from TRAP experiments carried out on total JR8 protein extracts. To investigate whether the basal level of telomerase activity of the tumour cell system plays a role in determining the cellular response to 17-AAG, we compared the cytotoxic activity of the drug in JR8 cells and in two JR8-derived clones that were stably transfected with a hammerhead ribozyme targeting the RNA template of telomerase and were characterized by a markedly lower telomerase activity than the parental cells. The cytotoxicity results indicated that both ribozyme-transfectant clones were almost 2-fold more sensitive to 72 h 17-AAG exposure than JR8 cells as a consequence of a more than double apoptotic response [in terms of the percentage of apoptotic nuclei in cells stained with propidium iodide and the percentage of Tdt-mediated dUTP nick-end labelling (TUNEL)-positive cells]. In summary, our results suggest that (i) telomerase is a target of GA and 17-AAG action and its inhibition may contribute to the cytotoxic activity of the drugs, (ii) the basal level of telomerase activity of the tumour cell system may also have a role in influencing 17-AAG cytotoxicity.Keywords
This publication has 39 references indexed in Scilit:
- Inhibition of telomerase activity by a distamycin derivative: effects on cell proliferation and induction of apoptosis in human cancer cellsEuropean Journal of Cancer, 2002
- Telomere maintenance in telomerase‐positive human ovarian SKOV‐3 cells cannot be retarded by complete inhibition of telomeraseFEBS Letters, 2002
- Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agentsEuropean Journal of Cancer, 2000
- Inhibition of telomerase activity by a cell‐penetrating peptide nucleic acid construct in human melanoma cellsFEBS Letters, 2000
- Hsp90 & Co. – a holding for foldingTrends in Biochemical Sciences, 1999
- The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycinCancer Chemotherapy and Pharmacology, 1998
- Recent Advances in the Study of hsp90 Structure and Mechanism of ActionTrends in Endocrinology & Metabolism, 1998
- Telomerase and cancer: revisiting the telomere hypothesisTrends in Biochemical Sciences, 1996
- Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system.Journal of Biological Chemistry, 1993
- A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell linesEuropean Journal of Cancer, 1993